The Leverkusen-based firm has been touting the potential of its pharmaceutical pipeline which it hopes will be able to help soften the blow of patent expiries on the blockbusters Xarelto and Eylea in the next few years.
Bayer AG has been discussing some of the 50 projects in its clinical development portfolio, including the promise offered by its newly-established cell and gene therapy (C>) platform.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
Adstiladrin sales hit €70m in first full year on the market
Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
Adstiladrin sales hit €70m in first full year on the market
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.
